Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial to evaluate two different doses of AQX 1125 in volunteers exposed to an environmental inflammatory stimulus

Next Previous
X
Search
Trial Profile

Phase IIa trial to evaluate two different doses of AQX 1125 in volunteers exposed to an environmental inflammatory stimulus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Apr 2013 Primary endpoint 'Inflammatory-markers' has been met according to an Aquinox media release.
    • 15 Nov 2011 Planned End Date changed to 31 Dec 2012.
    • 14 Nov 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top